Polynucleotides encoding E38N interferon gamma polypeptides
AssigneeMaxygen Holdings Ltd., a Cayman Corporation
InventorsJensen Anne Dam, Andersen Kim Vilbour, Hansen Christian Karsten
Life of this patent
Estimating the term…
Abstract
A conjugate exhibiting interferon gamma activity and comprising at least one first non-polypeptide moiety covalently linked to an IFG polypeptide, the polypeptide comprising an amino acid sequence that differs from that of a parent IFNG polypeptide in at least one introduced and/or at least one removed amino acid residue comprising an attachment group for the non-polypeptide moiety. The conjugate may be used for treatment of various diseases.
Claims21
1-35. (canceled)
A polynucleotide encoding an E38N interferon gamma (IFNG) polypeptide variant exhibiting IFNG receptor binding activity, said encoded E38N IFNG polypeptide variant having an amino acid sequence which
- (i) varies by 1 to 15 amino acid residue differences from the wild-type human IFNG polypeptide sequence shown in SEQ ID NO:
- 2 or from a C-terminally truncated fragment thereof wherein said fragment is C-terminally truncated by deletion of the last 1 to 15 amino acid residues relative to SEQ ID NO:
- 2;
- and
- (ii) is characterized by the substitution E38N.
Dependencies are inferred from the claim text.